Analysis
TRex Bio and Retension Pharmaceuticals both filed S-1 registration statements for Nasdaq IPOs on Friday, September 18, according to Yahoo Finance and Fierce Biotech. Neither company has disclosed a price range yet.
Two Different Companies, One Filing Day
- TRex Bio (ticker TRXB): developing medicines to restore immune balance and promote tissue repair in autoimmune and inflammatory disease. Its lead candidate, TRB-061, a tumor necrosis factor receptor 2 (TNFR2) agonist, is in early-stage trials for atopic dermatitis and related conditions, with data expected in mid-2027. Eli Lilly has agreed to invest directly in the IPO, a strategic validation similar to AbbVie's stake in ADARx's listing elsewhere in this issue.
- Retension Pharmaceuticals (ticker RTSN): based in Falls Church, Virginia, developing treatments for hypertension and cardiovascular disease. Its only product candidate, RTN-001, has already shown significant blood pressure reductions in two mid-stage clinical trials -- a more clinically de-risked profile than TRex's earlier-stage program.
“- Retension Pharmaceuticals (ticker RTSN): based in Falls Church, Virginia, developing treatments for hypertension and cardiovascular disease.”
Why Filing Together Matters
Two unrelated biotechs choosing the identical filing day is itself informative: bankers cluster filings into windows they judge open for investor appetite, and neither company wants to be first into an untested market or last into a saturated one. Pulse has tracked a broader fall 2026 biotech IPO wave building across the season, with Morningstar describing biotech and healthcare stocks as driving the current IPO resurgence even as tech listings have been comparatively quieter.
The Numbers In Context
Retension's single-asset, later-stage profile (RTN-001 already through two mid-stage trials) carries a meaningfully different risk-reward than TRex's earlier-stage TRB-061 program, even though both will likely be compared as a pair by investors simply because they filed together. That's a common trap in biotech IPO coverage: correlation in filing timing doesn't mean correlation in clinical risk, and treating the two as a single basket misses the real underwriting differences between them.
What Founders And GPs Should Watch
Which company prices first, and at what premium or discount to its filing-day comparables, will set an early read on whether investors are pricing clinical-stage risk (TRex) differently from later-stage, single-asset cardiovascular risk (Retension) in the current biotech IPO window -- a distinction that matters more to the next wave of biotech filers than the fact that these two happened to file on the same day.
For biotech founders watching this window from the outside, the more durable signal is the strategic-investor pattern repeating across nearly every major fall biotech listing -- Lilly into TRex, AbbVie into ADARx -- rather than any single company's specific terms. A pharma partner buying into the IPO itself, not just licensing later, is increasingly table stakes for a well-received biotech listing in this market, and its absence from a future filing would itself be worth noting.